Phase 2 trial results by dose (48 weeks) Phase 3 TRIUMPH-4 results (68 weeks) The phase 3 TRIUMPH-4 data, released in early 2026, confirmed and exceeded the phase 2 results
Future research focuses on advanced delivery systems and human trials for conditions such as Crohns disease, tendon injuries, and chronic ulcers
This peptide engineering technique uses D-amino acids arranged in reverse order, making the peptide more resistant to enzymatic breakdown while preserving its biological activity
Aviva Romm, a family medicine physician
TB-4 Frag + BPC-157 Arg 200mcg x 60 Caps For Research Use Only TB-4 Frag + BPC-157 Arg is a combination peptide research product supplied in capsule format
This naturally occurring substance aids in the transport of fatty acids into cells, where they are metabolized